BeStock  
Stocks › Biotechnology › SMMT

Summit Therapeutics SMMT

US equityMarket cap rank #1601BiotechnologyTop Gainers Yesterday
$9.95 −$0.62 (-5.87%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $10.08 +1.31%
Open$10.28
Prev close$10.57
Day range$9.89 – $10.61
Volume7.22M
Market cap$7.96B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-9.4x
CheapRich

Around its usual level · 44th percentile, 5-year average -23.5x

Price / book14.1x
CheapRich

Around its usual level · 40th percentile, 5-year average 31.0x

#5102 of 5338 stocks by PB (1 = cheapest)

Price / sales36,171.1x
CheapRich

Around its usual level · 55th percentile, 5-year average 32,526.4x

#5155 of 5161 stocks by PS (1 = cheapest)

P/E over five years

-225x-135x-44x46xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$18.77
Price vs. fair value-47.0%Trading below the estimate
Star rating★★★★★
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 14.09 – 30.97 40% (cheaper than usual) #5102 of 5338 (1 = cheapest)
PE -9.39 -8.66 -23.46 44% (cheaper than usual) –
PS 36,171.14 328.21 32,526.41 55% (pricier than usual) #5155 of 5161 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on SMMT.

Sign in to join the discussion.

Scroll to Top